Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06253702 · ClinicalTrials.gov registry record · Phase 4

Brain Blood Flow Responses to Stress: Sex Differences

A Phase 4 study of Cerebrovascular Disorders, sponsored by University of Wisconsin, Madison.

Completed
Registry status
Phase 4
Development phase
22
Enrollment target
1
Study location

NCT06253702 is a Phase 4 study of Cerebrovascular Disorders that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 22 participants, below the 1,094-participant average among 8 other Cerebrovascular Disorders trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06253702, a Phase 4 study of Cerebrovascular Disorders, has completed, sponsored by University of Wisconsin, Madison.

COMPLETED
Registry status
Phase 4
Development phase
22 participants
Enrollment target
1
Study location

Study Summary

Twenty-six otherwise healthy adults between 18-40 years of age composed of 13 males and 13 females will be enrolled in this study to determine how sex and sex hormones influence cerebral blood flow (CBF) control in healthy young adults without confounds of age or disease. Participants can expect to be on study for approximately 16 days.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Anastrozole
  • DRUG Indomethacin
  • DRUG Testosterone gel
  • DRUG Orilissa

Study Locations (1)

Wisconsin

  • University of Wisconsin - Madison

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2024-07-24
Est. Completion 2025-05-31
Phase Phase 4

Sponsor

University of Wisconsin, Madison

1,039 total trials

What the Registry Record Tells You About NCT06253702

The ClinicalTrials.gov registry entry for NCT06253702 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,094-participant average among 8 other Cerebrovascular Disorders trials with a reported enrollment target (98% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cerebrovascular Disorders appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.

NCT06253702 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.

Frequently Asked Questions

What is clinical trial NCT06253702 about?

NCT06253702 is a clinical study titled "Brain Blood Flow Responses to Stress: Sex Differences". Twenty-six otherwise healthy adults between 18-40 years of age composed of 13 males and 13 females will be enrolled in this study to determine how sex and sex hormones influence cerebral blood flow (CBF) control in healthy young adults without confounds of age or disease. Participants can expect to ...

What is the current status of trial NCT06253702?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2024-07-24. Estimated completion is 2025-05-31.

What conditions does trial NCT06253702 study?

This clinical trial studies the following conditions: Cerebrovascular Disorders.

What interventions are being tested in trial NCT06253702?

The interventions under investigation include: Placebo (DRUG), Anastrozole (DRUG), Indomethacin (DRUG), Testosterone gel (DRUG), Orilissa (DRUG).

Who is sponsoring clinical trial NCT06253702?

This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06253702 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cerebrovascular Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.